label: url

en: 腫瘍内微小環境の能動的制御に基づくDDSの開発とがん治療への応用

ja: 腫瘍内微小環境の能動的制御に基づくDDSの開発とがん治療への応用

en: CMC Publishing Co.,Ltd.

ja: 株式会社 シーエムシー出版


en: Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.

en: Springer

ja: Springer

en: For the systemic application of nucleic acids such as plasmid DNA and small interfering RNA, safe and efficient carriers that overcome the poor pharmacokinetic properties of nucleic acids are required. A cationic liposome that can formulate lipoplexes with nucleic acids has significant promise as an efficient delivery system in gene therapy. To achieve in vivo stability and long circulation, most lipoplexes are modified with PEG (PEGylation). However, we reported that PEGylated liposomes lose their long-circulating properties when they are injected repeatedly at certain intervals in the same animal. This unexpected and undesirable phenomenon is referred to as the accelerated blood clearance (ABC) phenomenon. Anti-PEG IgM produced in response to the first dose of PEGylated liposomes has proven to be a major cause of the ABC phenomenon. Therefore, in a repeated dosing schedule, the detection of anti-PEG IgM in an animal treated with PEGylated lipoplex could be essential to predict the occurrence of the ABC phenomenon. This chapter introduces a method for the evaluation of serum anti-PEG IgM by a simple ELISA procedure, and describes some precautions associated with this method.


en: Cationic liposomes and tumour vasculature targeting: a therapeutic approach that has potential for solid tumours.

en: Souto, E.B. (Ed.), i-Smithers - Creative Publishing Solutions


en: Breaking the barriers to tumor-targeting via nanocarrier-based drug delivery to the tumor microenvironment.

en: Nova Science Publishers

ja: Nova Science Publishers


en: Complexation of siRNA and pDNA with cationic liposomes: The important aspects in lipoplex preparation.

en: A chapter, Liposomes, Methods Mol. Biol.

en: In the last two decades, cationic liposomes have been investigated as vehicles for nucleic acids [plasmid DNA (pDNA) and small interfering RNA (siRNA)] delivery in vitro and in vivo. The formation of cationic liposomes-nucleic acids complexes, termed lipoplexes, depends on a number of experimental variables. The quality of the nucleic acid and the cationic liposome as well as the selection of diluents for diluting the concentrated stocks strongly affect the resulting lipoplexes and their efficiency of gene-expression or gene-silencing effect following transfection. In addition, the molar ratio of cationic lipid nitrogen (N) to siRNA or pDNA phosphate (P) (N/P ratio) influences the final characteristics of the lipoplexes, such as size, surface zeta potential, and reproducibility, thereby reflecting their efficiency following transfection. The methods presented in this chapter could be helpful to obtain reliable and reproducible lipoplexes and experimental results.


en: Synergistic antitumor activity of metronomic dosing chemotherapy in combination with liposomal anticancer drug.


en: Unexpected reactions by in vivo application of PEGylated liposomes.

en: Springer Science + Business Media, New York, USA


en: 第10章医学薬学でのリポソーム応用 1節リポソームと細胞の相互作用

ja: 第10章医学薬学でのリポソーム応用 1節リポソームと細胞の相互作用

en: NTS Inc.

ja: 株式会社エヌ·ティー·エス


en: 第10章医学薬学でのリポソーム応用 3節長期血中滞留性リポソーム

ja: 第10章医学薬学でのリポソーム応用 3節長期血中滞留性リポソーム

ja: 株式会社エヌ·ティー·エス


en: 有効性の向上とバイオアベイラビリティー

ja: 有効性の向上とバイオアベイラビリティー

en: 総合製剤学

ja: 総合製剤学


en: Adv. Drug Deliv. Rev. (Theme Editor) --- The pharmacokinetics of liposomes for tumor targeting


en: ライフサイエンスにおけるリポソーム·実験マニュアル

ja: ライフサイエンスにおけるリポソーム·実験マニュアル

en: シュプリンガー·フェアラーク東京

ja: シュプリンガー·フェアラーク東京


en: ライフサイエンスにおけるリポソーム 実験マニュアル 寺田弘，吉村哲郎編 --- ドラッグキャリアーとしてのリポソーム

en: Springer-Verlag

ja: Springer-Verlag


en: 生物薬剤学ー最近の進歩 伊賀立二，奥村勝彦編 --- リポソームを利用した体内挙動の制御

en: (株) 薬業時報社

ja: (株) 薬業時報社


en: Liposomes:Are they effective drug carriers?Topics in Pharmaceutical Sciences 1983